Ampicillin

Co-fluampicil is indicated for the treatment of severe infections where the causative organism is unknown, and for mixed infections involving β- lactamase-producing staphylococci.

In general practice:

Chest infections, ENT infections, skin and soft tissue infections and patients with an underlying pathology which makes them more susceptible to infections. In hospital use (if laboratory tests are not yet available): severe respiratory infections, post-operative chest and wound infections, septic abortion, puerperal fever, septicaemia, prophylaxis in major surgery and infections in patients receiving immunosuppressive therapy.

The spectrum of activity of co-fluampicil also makes it suitable for the treatment of many mixed infections, particularly those where β-lactamase- producing staphylococci are suspected or confirmed.

INDICATIONS AND USAGE

Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H.

influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria.

, penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy.

The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis. , and Shigella spp. (dysentery) usually respond to oral or intravenous therapy.